Analyst Edward White of H.C. Wainwright reiterated a Buy rating on Karyopharm Therapeutics (KPTI – Research Report), retaining the price target of $7.00. Edward White has given his Buy rating
Analyst Edward White of H.C. Wainwright reiterated a Buy rating on Karyopharm Therapeutics (KPTI – Research Report), retaining the price target of $7.00. Edward White has given his Buy rating
הקונצנזוס להכנסות בשנת 2024 הוא 152.90 מיליון דולר. החברה מצפה כי המזומנים הנוכחיים שלה, שווי המזומנים וההשקעות, יחד עם ההכנסות ממכירות המוצר נטו של XPOVIO, הסכמי רישוי ואמצעי חיסכון בעלויות,
Reports Q3 revenue $38.8M, consensus $38.15M. “This quarter, we delivered our third consecutive quarter of U.S. XPOVIO net product revenue growth in the highly competitive multiple myeloma marketplace. On our
Consensus for 2024 revenue is $152.90M. The company expects that its existing cash, cash equivalents and investments, the revenue it expects to generate from XPOVIO net product sales and its
Barclays analyst Peter Lawson maintained a Buy rating on Karyopharm Therapeutics (KPTI – Research Report) today and set a price target of $5.00. The company’s shares closed yesterday at $0.99.